EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting Pediatric Glioblastomas by Combining OLIG2 Inhibitor CT-179 with Fractionated Radiation in a Panel of Patient-Derived Orthotopic Xenograft Mouse Models

Holly Lindsay, Yuchen Du, Lin Qi iD, Huiyuan Zhang, Sibo Zhao iD, Frank K Braun iD, Mari Kogiso, Clifford Stephan iD, Gordon Alton, Gregory Stein, Graham Beaton, Santosh Kesari iD und 8 weitere

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27031543 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Holly Lindsay und 19 weiteren Autor:innen. Beteiligte Einrichtung: Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, TX 77030, USA. Hauptthemen laut MEDLINE: Oligodendrocyte Transcription Factor 2, Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH/NCI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The poor clinical outcomes of pediatric high-grade glioma (pHGG) highlight the urgent need for new therapies. Oligodendrocyte lineage transcription factor 2 (OLIG2) is a pro-mitotic transcription factor highly expressed in glioma stem cells and may represent a novel therapeutic target. To evaluate the therapeutic efficacy of an OLIG2 inhibitor CT-179 in pHGG, we determined the OLIG2 mRNA expression in 10 patient-derived orthotopic xenograft (PDOX) models. In vitro activities of CT-179 were analyzed in monolayer and neurosphere cells (0–10 µM) with and without radiation (XRT) (0–8 Gy), brain penetration was evaluated in tumor-bearing PDOX mice, and in vivo efficacy was determined at 15–240 mg/kg (oral) alone or combined with XRT (2 Gy/day × 5 days). Changes in animal survival times were analyzed using the Kaplan–Meier method, followed by pair-wise comparisons. Increased OLIG2 mRNA expression was detected in seven out of ten PDOX models. CT-179 inhibited cell viability in a time- and dose-dependent manner in all eight pGBM xenograft tumors (IC50 0.03–10 µM) and was potentiated by XRT (0.03–1 µM). Oral gavage (24 mg/kg) of CT-179 for 5 days led to effective penetration in mouse cerebrum (3232.7 ± 569.2 ng/g), cerebellum (1563.3 ± 269.6 ng/g), brain stem (1685.3 ± 309 ng/g), and PDOX tumors (1814 ± 110.3 ng/g) vs. 361.3 ± 1.5 ng/mL in serum. CT-179 alone was not active at 200 mg/kg in four models, although it was moderately effective at 240 mg/kg in one model. When combined with XRT, a significant extension of animal survival times was observed in two out of four models. Doses needed to eliminate OLIG2 expression in vitro varied from 0.3 to >1 µM in pGBM cells. In summary, our data showed that orally administered CT-179 penetrated the blood–brain barrier (BBB) and exhibited potential for inhibiting pGBM growth when combined with XRT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oligodendrocyte Transcription Factor 2GlioblastomaBrain NeoplasmsAnimalsHumansMiceXenograft Model Antitumor AssaysChildFemaleCell Line, TumorMaleCell SurvivalDose Fractionation, Radiation

Stichwörter der Autor:innen

GBMOLIG2PDOXpediatric brain tumorradiationtherapeutic efficacy

Substanzen

Oligodendrocyte Transcription Factor 2OLIG2 protein, human

Autor:innen und Institutionen

  • Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, TX 77030, USA.
  • School of Medicine, University of Colorado Anschutz Medical Campus, Children's Hospital Colorado Center for Cancer and Blood Disorders, Aurora, CO 80045, USA.
  • Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
  • Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin 541004, China.
  • Ben Towne Center for Childhood Cancer and Blood Disorders, Seattle Children's Research Institute, Seattle, WA 98101, USA.
  • Cook Children's Neuro-Oncology, Dallas, TX 76104, USA.

ORCID-Profile: Lin Qi, Sibo Zhao, Frank K Braun, Clifford Stephan, Santosh Kesari, Steve Neuhauser, Tim Stearns, Carol J Bult, Beverly Teicher, Xiao-Nan Li

Förderung

  • NCI NIH HHS
  • NIH/NCI

Zitieren

APA

Lindsay, H., Du, Y., Qi, L., Zhang, H., Zhao, S., Braun, F. K., Kogiso, M., Stephan, C., Alton, G., Stein, G., Beaton, G., Kesari, S., Neuhauser, S., Stearns, T., Chuang, J., Jocoy, E. L., Bult, C. J., Teicher, B., Smith, M. A., & Li, X. N. (2026). Targeting Pediatric Glioblastomas by Combining OLIG2 Inhibitor CT-179 with Fractionated Radiation in a Panel of Patient-Derived Orthotopic Xenograft Mouse Models. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27031543

Vancouver

Lindsay H, Du Y, Qi L, Zhang H, Zhao S, Braun FK, et al. Targeting Pediatric Glioblastomas by Combining OLIG2 Inhibitor CT-179 with Fractionated Radiation in a Panel of Patient-Derived Orthotopic Xenograft Mouse Models. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27031543

BibTeX
@article{Lindsay2026,
  author = {Lindsay, Holly and Du, Yuchen and Qi, Lin and Zhang, Huiyuan and Zhao, Sibo and Braun, Frank K and Kogiso, Mari and Stephan, Clifford and Alton, Gordon and Stein, Gregory and Beaton, Graham and Kesari, Santosh and Neuhauser, Steve and Stearns, Tim and Chuang, Jeff and Jocoy, Emily L and Bult, Carol J and Teicher, Beverly and Smith, Malcolm A and Li, Xiao-Nan},
  title = {Targeting Pediatric Glioblastomas by Combining OLIG2 Inhibitor CT-179 with Fractionated Radiation in a Panel of Patient-Derived Orthotopic Xenograft Mouse Models},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27031543}
}
Kostenlos starten →